Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A

This publication has 116 references indexed in Scilit:

• The Effect of Factor VIII Deficiencies and Replacement and Bypass Therapies on Thrombus Formation under Venous Flow Conditions in Microfluidic and Computational Models
  PLOS ONE, 2013
• Barriers and perceived limitations to early treatment of hemophilia
  Journal of Blood Medicine, 2013
• Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
  PLOS ONE, 2013
• Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
  Blood, 2012
• Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice
  Blood, 2009
• Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A
  Expert Opinion on Biological Therapy, 2009
• Assessment of Treatment Practice Patterns for Severe Hemophilia A: A Global Nurse Perspective
  Acta Haematologica, 2008
• Defining ‘full‐length’ recombinant factor VIII: a comparative structural analysis
  Haemophilia, 2006
• The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor
  Haemophilia, 2006
• Pharmacokinetics of recombinant factor VIII (Kogenate‐FS^®) in children and causes of inter‐patient pharmacokinetic variability
  Haemophilia, 2006